Dr. Hill on Next Steps for Research Exploring CAR T-Cell Therapy in MCL
Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.
Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician at Taussig Cancer Institute, as well as an assistant professor of Hematology and Oncology at the Cleveland Clinic, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma (MCL).
Two questions regarding the use of CAR T-cell therapy in MCL involve moving the therapy up into earlier lines of treatment and using it in combination with other agents, says Hill. Thus far, there have been no compelling reasons to combine other therapies with CAR T-cell treatment for lymphoma, Hill explains. However, studies are looking into this concept, adds Hill.
In terms of using CAR T-cell therapy in earlier lines of treatment, many ongoing discussions are focused on examining the use this approach in certain populations with high-risk disease, according to Hill. These populations include those with TP53 mutations or a blastoid variant of MCL, a subtype that has historically yielded particularly poor outcomes with traditional chemotherapy and high-dose chemotherapy, as is used in autologous stem cell transplant, concludes Hill.
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
